TWIST

New Tovolo® Mini Ice Cylinders and Trays Offer Easy and Inexpensive Solutions for Creating Trendy Nugget Ice at Home

Retrieved on: 
Thursday, March 14, 2024
TWIST, Drink, BPA, Charcoal, Twist, Ice, MSRP, Amazon (company), Mini

1: Mini Ice Cylinders – Squeeze & ReleaseThis whimsical solution is fun to use and satisfyingly addicting! Featuring a compact-sized, squeezable design, the innovative and easy-to-use cylinder makes enough ice to chill more than two drinks--creating 200 mini ice cubes per batch. Simply squeeze to pop the ice free.    

Key Points: 
  • Tovolo®, a leader in go-to kitchen innovations, is changing the game by bringing this trendy ice option to consumer kitchens with two innovative new Mini Ice products.
  • Tovolo® is changing the game by bringing popular nugget ice to consumer kitchens with innovative new Mini Ice products.
  • The Tovolo® Mini Ice products are designed to make the popular nugget-style ice easily and affordably.
  • MSRP $17.99
    The unique diamond-shaped orientation of the ice on the Twist & Release Mini Ice Trays makes popping the ice out simple.

Tevra Brands to Showcase New Pet Wellness and Behavioral Health Products at Booth #5464 During Global Pet Expo, March 20 - 22

Retrieved on: 
Monday, March 4, 2024
TWIST, Well, Pet, Chamomile, Skin, Anxiety, Love, Research, Bacillus coagulans, Consumer, Biotin, Postbiotic, Global Pet Expo, Absorption, Marketing, Dog, Glucosamine, Cartilage, Parent, Dental care, Harmony, Vitamin E, Pheromone, University, Texas Tech University, Dicarboxylic acid, Joint, Hip, Ligament, Digestion, Cat, Fatty acid, Heart, Physiology, Multi, Immune system

OMAHA, Neb., March 4, 2024 /PRNewswire-PRWeb/ -- Tevra Brands will exhibit at Global Pet Expo, the pet industry's premier event from March 20 to 22 in Orlando, and introduce a host of new products, headlined by five TWIST + LICK Well Gel solutions. Additionally, the brand will unveil a new answer to giving pills to discerning canines with the TWIST + LICK SimPill, as well as a full line of new Harmony Pet solutions that meet the calming needs of dogs and cats with proprietary, pheromone-activated products to deliver stress relieving results on the go.

Key Points: 
  • According to Caryn Stichler, vice president of marketing for Tevra Brands, "Tevra Brands empowers pet owners with solutions that work, and we take pride in developing groundbreaking products and delivery systems that go beyond traditional methods.
  • As a result, many pet owners are struggling to keep their beloved, four-legged family members in their homes.
  • Tevra Brands and their products help pet owners keep their fur-kids at home for the love, companionship and support they all cherish."
  • Visit booth #5464 at Global Pet Expo to see the entire line of T+L Well Gels, the new T+L SimPill and the Harmony product lines.

CENTOGENE Reports First Half 2023 Financial Results

Retrieved on: 
Thursday, September 7, 2023
TWIST, Saskatchewan River Sturgeon Management Board, Spinal muscular atrophy, GCC, Tax, G&A, Cystic fibrosis transmembrane conductance regulator, Patient, R, Development, WES, Sequence, Disease, Annual general meeting, Genetics, Research, WGS, Growth, Diagnosis, Whole genome sequencing, Total, Gaucher's disease, Observational study, LRRK2, DNA sequencing, History, Warburg Micro syndrome, JV, DSM-IV codes, Supervisory board, Gulf Cooperation Council, Therapy, Cancer, Partnership, Public Investment Fund, Mox, Medication, Joint venture, CFTR, Twist Bioscience, EBITDA, Fine chemical, Cryptocurrency, Pharmaceutical industry, Clothing, Video game, Palladium, Pharma

and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its unaudited financial results for the six months ended June 30, 2023.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its unaudited financial results for the six months ended June 30, 2023.
  • Cost of sales increased by €2,692 thousand, or 20.7%, to €15,728 thousand for the first half of 2023, from €13,036 thousand for the first half of 2022.
  • General administrative expenses decreased by €112 thousand, or 0.6%, to €17,172 thousand for the first half of 2023, from €17,284 thousand for the first half of 2022.
  • The decrease is mainly due to the increase in consumable expenses on approximately €1,601 thousand for the first half of 2023.

CENTOGENE Reports Full Year 2022 Financial Results

Retrieved on: 
Tuesday, May 16, 2023
TWIST, Galloway Mowat syndrome, IVDR, Spinal muscular atrophy, Denali, Syndrome, Audit committee, Data analysis, Patient, Fabry disease, Muscular dystrophy, Sequence, Disease, Genetics, Mass meeting, Research, Alport syndrome, Whole genome sequencing, Dysautonomia, Growth, Diagnosis, Total, Safety, DSM-IV codes, Gaucher's disease, Observational study, LRRK2, COVID-19, DNA sequencing, Supervisory board, Frontotemporal dementia, Therapy, Cancer, Epilepsy, TRE, CE, Software as a service, Hypotonia, Bank statement, Mox, Hypoventilation, Intellectual disability, Twist Bioscience, EBITDA, Physician, CNTG, Biogen, Fine chemical, Cryptocurrency, Pharmaceutical industry, Medical device, Pharma

and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.
  • “2022 reaffirms CENTOGENE’s focus and dedication to becoming the essential data-driven partner in rare and neurodegenerative diseases.
  • By strategically managing our expenses, we seek to enhance the stability of our balance sheet and foster sustainable financial performance,” added Miguel Coego, Chief Financial Officer at CENTOGENE.
  • These customizable partnering solutions include Insight Reports, which are tailored data analysis reports that seamlessly enable partners to answer ad hoc research questions via real-world data.

InventHelp Inventor Develops Modified Twist-Off Bottle Cap for Beverages (CWC-194)

Retrieved on: 
Tuesday, April 25, 2023
TWIST, Finger, Drink, Multimedia, E, Sale

PITTSBURGH, April 25, 2023 /PRNewswire/ -- "I wanted to create a modified twist-off bottle cap that would ease the task of opening a bottled beverage," said an inventor, from Dix, Ill., "so I invented the E - Z TWIST.

Key Points: 
  • PITTSBURGH, April 25, 2023 /PRNewswire/ -- "I wanted to create a modified twist-off bottle cap that would ease the task of opening a bottled beverage," said an inventor, from Dix, Ill., "so I invented the E - Z TWIST.
  • My design would eliminate the hassle of squeezing standard caps to open bottles, which can be rough on the hands and fingers."
  • The invention provides an improved packaging design for beverages.
  • In doing so, it offers an easier way to remove the twist-off bottle cap.

DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Twist Bioscience Corporation Securities Fraud Class Action Lawsuit

Retrieved on: 
Monday, January 30, 2023
Class Action Lawsuit, Professional Services, Legal, TWIST, Public expenditure, DNA, Biotechnology, Peters, Lead, District court, LLP, Fraud, COPY, Charles Ponzi, Scorpion, Defendant, Class, Growth, Court, Private investigator, Cryptocurrency

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against Twist Bioscience Corporation (“Twist”) ( NASDAQ: TWST ) on behalf of investors who purchased or acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive (the “Class Period”).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against Twist Bioscience Corporation (“Twist”) ( NASDAQ: TWST ) on behalf of investors who purchased or acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive (the “Class Period”).
  • This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.
  • Kessler Topaz Meltzer & Check, LLP encourages Twist investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Twist Bioscience Corporation (NASDAQ: TWST)

Retrieved on: 
Thursday, February 9, 2023
TWIST, DNA, Charles Ponzi, Biotechnology, Lead, LLP, Court, COPY, Peters, Class, Public expenditure, Defendant, District court, Scorpion, Growth, Fraud, Private investigator, Insurance

This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.

Key Points: 
  • This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.
  • Kessler Topaz Meltzer & Check, LLP encourages Twist investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Twist Bioscience Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Twist Bioscience Corporation Shareholders of Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Saturday, February 4, 2023
TWIST, DNA, Charles Ponzi, Biotechnology, Lead, LLP, Court, COPY, Peters, Class, Public expenditure, Defendant, District court, Scorpion, Growth, Fraud, Private investigator, Insurance

This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.

Key Points: 
  • This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.
  • Throughout the Class Period, Defendants repeatedly assured investors that the company possessed innovative proprietary technology relating to its synthetic DNA products that positioned Twist for significant future growth.
  • Kessler Topaz Meltzer & Check, LLP encourages Twist investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors that the Firm Has Filed a Securities Fraud Class Action Lawsuit Filed against Twist Bioscience Corporation

Retrieved on: 
Sunday, January 29, 2023
TWIST, DNA, Charles Ponzi, Biotechnology, Lead, LLP, Court, COPY, Peters, Class, Public expenditure, Defendant, District court, Scorpion, Growth, Fraud, Private investigator, Insurance

This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.

Key Points: 
  • This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.
  • 3:22-cv-08168, was filed in the United States District Court for the Northern District of California and is assigned to the Honorable Edward J. Davila.
  • Kessler Topaz Meltzer & Check, LLP encourages Twist investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Kessler Topaz Meltzer & Check, LLP Encourages Twist Bioscience Corporation Investors with Substantial Loss to Contact the Firm in Regards to Securities Class Action Lawsuit Filed against Twist Bioscience Corporation

Retrieved on: 
Monday, January 23, 2023
TWIST, DNA, Charles Ponzi, Biotechnology, Lead, LLP, Court, COPY, Peters, Class, Public expenditure, Defendant, District court, Scorpion, Growth, Fraud, Private investigator, Insurance

This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.

Key Points: 
  • This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No.
  • 3:22-cv-08168, was filed in the United States District Court for the Northern District of California and is assigned to the Honorable Edward J. Davila.
  • Kessler Topaz Meltzer & Check, LLP encourages Twist investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.